Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Low-Dose MMF for Proliferative Lupus Nephritis in Children
NCT07675291Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2026
- Primary completion
- Dec 2028
01
Overview
Randomised trial of rituximab and mycophenolate mofetil in lupus nephritis (LN) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Complete response at 6 months, Partial response at 6 months and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
rituximabmycophenolate mofetil
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07675291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675291.